English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16959/19260 (88%)
Visitors : 7635362      Online Users : 200
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/30078


    標題: 探討牛樟芝萃取物對於以化學治療藥物處理肝癌細胞的影響
    To investigate the effect of Antrodia cinnamomea extracts on chemical therapeutic drugs treatment in human hepatoma cells.
    作者: 李姿融
    貢獻者: 生物科技系
    洪瑞祥
    關鍵字: Huh-7
    遷移
    牛樟芝萃取物
    肝癌
    Sorafenib
    Sorafenib
    Antrodia Cinnamomea extracts
    hepatocellular carcinoma
    migration
    Huh-7
    EAC
    日期: 2016
    上傳時間: 2016-12-21 15:34:13 (UTC+8)
    摘要: 肝癌為世界第二大癌症;癌症死亡率第三的癌症,許多藥物被用來治療肝癌如doxorubicin或sorafenib等藥物。本研究中我們的目的主要為探討牛樟芝萃取液(EAC)對於Sorafenib誘導肝癌細胞死亡機制的影響。當合併EAC與sorafenib處理時顯著抑制Huh-7和HepG2的生長,而在Western blot分析出多種訊號顯示合併藥物處理可以調節MAPK和NF-B的路徑達到抗腫瘤的功效,也會誘導細胞週期蛋白表達的改變。以傷口癒合試驗探討合併藥物治療對Huh-7細胞遷移機制的影響;以real time-PCR檢測合併治療對Huh-7細胞的轉移相關蛋白的表現。並且以動物試驗探討合併藥物治療對於肝腫瘤生長的影響。發現合併治療有抑制MAPK家族及細胞週期相關蛋白的表達、抑制增殖能力和降低遷移相關蛋白的表現量。結果顯示EAC能增強Sorafenib誘導細胞死亡能力、增加肝癌細胞對sorafenib的敏感度及抑制肝癌細胞的遷移能力,依此結果運用在肝癌治療中建議EAC可以降低Sorafenib藥量,對於因過量使用Sorafenub患者而產生的副作用的患者,將有相當大的助益,對於未來將進一步探討Sorafenib在EAC的輔助下其更多的機制。
    Hepatocellular carcinoma (HCC) is the second-leading cause of cancerworldwide and the third-leading cause of cancer death, and varied drugs wereused to treatment in HCC such as doxorubicin or sorafenib. In the present study, we want to investigate the effects Antrodia Cinnamomea extracts (EAC) on the anticancer activity of sorafenib treatment in HCC cells. First of all, combination treatment resulted in significant growth inhibition in HepG2 and Huh-7 cells.Western blot analysis of various signaling markers revealed the ability ofsorafenib with EAC to target pathways mediated by mitogen-activated protein(MAP) kinase and NF-kB, of which the concerted action underlined itsantitumor efficacy. The combination treatment also induced alternation of cyclin proteins expression. Besides, the Wound Healing assay were perform to study the influence of combined drugs treatment on Huh-7 cells migration mechanism.After that, the MMP-2 and MMP-9 Protein expression of combined drugs treatment on Huh-7 was detected by Quantitative PCR. Finally, in animal model assay were performed to study the influence of combined drugs treatment on HCC tumor growth and protein expression. We found that combination IV significantly inhibition of MAPK family and cell cycle protein expression, inhibition of cell proliferation and reduce protein expression of migration. Our results indicate that EAC can enhance sorafenib for the treatment of HCC cells and enhance sensitivity of sorafenib and inhibition of migration in HCC cells.These results suggest that the EAC is very helpful to reduce the amount of sorafenib, and decreased the side effects of sorafenib on patients in further. We will be further investigating sorafenib in the auxiliary EAC its additional mechanisms.
    Appears in Collections:[生物科技系(所)] 博碩士論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML159View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback